Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Betting big on talent, resources, and the ecosystem required for innovation and enterprise, Prime Minister Narendra Modi invited stakeholders to ideate in India, innovate in India and Make in India for the world
Two out of three people under the age of 40 are at risk of prediabetes
Data demonstrates Ronapreve reduced risk of hospitalisation in certain patients and reduced risk of symptomatic Covid-19 infections in people exposed to the virus
The centre has an initial capacity of 500 FTEs
The consideration for the acquisition is US $ 2.25 million
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
A Sanofi R&D executive will join the Gyroscope Clinical Advisory Board to advise on matters related to the development of GT005 for geographic atrophy (GA).
Subscribe To Our Newsletter & Stay Updated
